The goal of this clinical research study is to find the highest tolerable dose of the
combination of Yervoy® (ipilimumab) with Revlimid® (lenalidomide) that can be given to
patients with advanced cancer. The safety of these drugs will also be studied.
Ipilimumab is designed to increase the immune system's ability to fight cancer.
Lenalidomide is designed to change the body's immune system. It may also interfere with the
development of tiny blood vessels that help support tumor growth. This may decrease the
growth of cancer cells.